| Bioactivity | Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein[1][2]. | |||||||||
| Invitro | Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils[1].Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers[1]. | |||||||||
| In Vivo | Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau[2].Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29[2]. Animal Model: | |||||||||
| Name | Cl-NQTrp | |||||||||
| CAS | 185351-23-9 | |||||||||
| Formula | C21H15ClN2O4 | |||||||||
| Molar Mass | 394.81 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. V Guru KrishnaKumar, et al. Mechanistic insights into remodeled Tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids. Sci Rep. 2018 Jan 8;8(1):71. [2]. Moran Frenkel-Pinter, et al. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. Neurodegener Dis. 2017;17(2-3):73-82. |
Cl-NQTrp
CAS: 185351-23-9 F: C21H15ClN2O4 W: 394.81
Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length ta
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.